Plate Nº 56 · recorded October 13, 2026
Health & Medicine ResearchReported finding
NEJM Publishes Phase 3 Bepirovirsen Results in Chronic Hepatitis B
Phase 3 results of bepirovirsen for chronic hepatitis B have now appeared in the New England Journal of Medicine, in a program aimed at the 296 million people affected worldwide. The paper lands at nejm.org.
By Marcus Bennett3 min read564 words
In brief
- NEJM has published Phase 3 results of bepirovirsen titled 'Phase 3 Results of Bepirovirsen Treatment for Chronic Hepatitis B Virus Infection' at nejm.org
- WHO estimates put global chronic hepatitis B prevalence at roughly 296 million people, with about 800,000 deaths annually from cirrhosis and liver cancer
- Bepirovirsen is a 20-mer antisense oligonucleotide that targets HBV messenger RNA for degradation by the host enzyme RNase H
- Standard nucleoside analogues — entecavir, tenofovir, and derivatives — typically require lifelong dosing and rarely eliminate cccDNA
- HBsAg seroclearance has become the field's working definition of functional cure and is the typical primary endpoint for HBV Phase 3 trials
Phase 3 results of bepirovirsen for chronic hepatitis B have now appeared in the New England Journal of Medicine, in a development program targeting the roughly 296 million people affected worldwide. The paper, titled Phase 3 Results of Bepirovirsen Treatment for Chronic Hepatitis B Virus Infection, lands at nejm.org and marks the drug's late-stage evaluation in print.
For hepatologists and infectious-disease clinicians tracking HBV therapeutics, the publication is the headline event. Whether the trial supports a new paradigm of finite-course treatment will depend on numbers spelled out inside the full paper. Coverage here addresses the publication itself; specific efficacy data sit inside the journal article.
Why is chronic hepatitis B hard to cure?
The pathogen persists inside infected hepatocytes as covalently closed circular DNA, or cccDNA, a stable reservoir that supports ongoing viral transcription even when replication is pharmacologically suppressed. Standard nucleoside analogues — entecavir, tenofovir, and their derivatives — reduce HBV DNA to undetectable levels in most patients, but they rarely eliminate cccDNA. Patients therefore usually stay on therapy for life.
Loss of hepatitis B surface antigen, known as HBsAg seroclearance, has emerged as the field's working definition of functional cure, because it is the rare event that allows patients to stop therapy without relapse.
Takeaway: standard therapy suppresses but does not cure, which is why an HBsAg-loss endpoint matters.
How does bepirovirsen work?
Bepirovirsen is a 20-mer antisense oligonucleotide, a chemically modified strand designed to bind HBV messenger RNA and trigger its destruction by the host enzyme RNase H. By engaging viral transcripts directly, the drug aims to cut both viral DNA production and the source of HBsAg.
The mechanism matters because HBsAg itself has been implicated in immune exhaustion. Circulating surface antigen in chronic infection may blunt T-cell responses, so its reduction could, in principle, restore some antiviral immunity. Combination strategies that pair bepirovirsen with conventional antivirals or immunomodulators have drawn particular interest in earlier-stage work.
Takeaway: by degrading viral mRNA, the drug attacks the transcripts that produce surface antigen.
What does a Phase 3 readout carry?
A Phase 3 publication is the kind of evidence that regulators in the United States, Europe, and China review for marketing authorization. For chronic HBV, where approved products are typically generics with long safety records, a successful antisense could break the indefinite-treatment pattern by enabling a finite regimen that achieves durable HBsAg loss.
Trialists tend to report results in layers: primary endpoint first, key secondary endpoints next, then subgroup and safety data. Practitioners should resist any summary until they read the published endpoint definitions, the response criteria, and the duration of follow-up.
Takeaway: this trial will be judged on durability and breadth of HBsAg loss, not just on suppression.
What should practitioners watch next?
The hepatitis B community now holds a Phase 3 paper in NEJM. Pending the figures and tables inside it, field planning will shift accordingly: regulatory submissions, label discussions, and combination protocols hinge on what the trial showed. For patients, the question remains the one the field has chased for years — can a finite course of treatment produce a sustained functional cure, and at what frequency?
Until those figures emerge, the publication functions more as a milestone than a verdict — the data inside will decide which.
Takeaway: the paper, not the press release, will set the next quarter's HBV agenda.
via Google News: Clinical Trials (Source)
More from Marcus Bennett
Show full bio
News editor covering regulation, policy and their impact on general science news at SciBeat.
243 articles
Nearby plates
- FDA asks uniQure for more data on AMT-130 Huntington's gene therapy
- Pausing Arthritis Drugs After COVID Booster Doubles Flare Risk
- Measles Antibodies Could Become First Monoclonal Therapy in Two Years
- Roche Halts Two Huntington's Disease Drug Programmes
- Experimental Pill Trial Aims to Slow Congo's Deadliest Ebola Outbreak